Comparative Pharmacology
Head-to-head clinical analysis: ARDUAN versus BOTOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARDUAN versus BOTOX.
ARDUAN vs BOTOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nondepolarizing neuromuscular blocking agent; competitively blocks acetylcholine at nicotinic receptors at the motor end-plate.
Botulinum toxin type A inhibits acetylcholine release at the neuromuscular junction by cleaving SNAP-25, a protein required for synaptic vesicle fusion.
Initial IV bolus of 0.08 mg/kg followed by incremental doses of 0.01 mg/kg to maintain neuromuscular blockade
Intramuscular injection: 20-200 units per treatment session, repeated every 3-6 months as needed. Maximum total dose: 400 units per 3 months.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5-2.9 hours); prolonged in renal impairment
Terminal elimination half-life is approximately 10-12 hours for the toxin complex in plasma; however, neuromuscular blocking effect persists for 3-6 months due to irreversible inhibition of SNARE proteins and slow nerve terminal regeneration.
Primarily renal (60-70% unchanged drug); biliary/fecal (20-30%)
Primarily hepatic metabolism with biliary excretion of metabolites; renal excretion of intact toxin is negligible (<1%). Fecal elimination of metabolites accounts for >99% of clearance.
Category C
Category C
Neuromuscular Blocker
Neuromuscular Blocker